Vaccinex, Inc. (VCNX): Price and Financial Metrics


Vaccinex, Inc. (VCNX)

Today's Latest Price: $5.40 USD

0.18 (-3.23%)

Updated Aug 12 1:41pm

Add VCNX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

VCNX Stock Summary

  • Vaccinex Inc's stock had its IPO on August 9, 2018, making it an older stock than merely 4.39% of US equities in our set.
  • The ratio of debt to operating expenses for Vaccinex Inc is higher than it is for about only 0.36% of US stocks.
  • VCNX's price/sales ratio is 216.5; that's higher than the P/S ratio of 98.17% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Vaccinex Inc, a group of peers worth examining would be ERYP, NVEC, ACIU, TLC, and AFMD.
  • VCNX's SEC filings can be seen here. And to visit Vaccinex Inc's official web site, go to www.vaccinex.com.
VCNX Daily Price Range
VCNX 52-Week Price Range

VCNX Stock Price Chart Technical Analysis Charts


VCNX Price/Volume Stats

Current price $5.40 52-week high $12.23
Prev. close $5.58 52-week low $3.22
Day low $5.30 Volume 252,190
Day high $5.90 Avg. volume 246,990
50-day MA $4.89 Dividend yield N/A
200-day MA $4.86 Market Cap 89.88M

Vaccinex, Inc. (VCNX) Company Bio


Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.





VCNX Latest News Stream


Event/Time News Detail
Loading, please wait...

VCNX Latest Social Stream


Loading social stream, please wait...

View Full VCNX Social Stream

Latest VCNX News From Around the Web

Below are the latest news stories about Vaccinex Inc that investors may wish to consider to help them evaluate VCNX as an investment opportunity.

Thinking about buying stock in Barnes & Noble Education, Vaccinex Inc, Seelos Therapeutics, PDS Biotechnology, or SINTX Technologies?

NEW YORK, July 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNED, VCNX, SEEL, PDSB, and SINT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | July 17, 2020

3 Stocks Flashing Signs of Strong Insider Buying

Confused by the current financial landscape? You’re not alone. Unemployment is high, the Street is expecting a rough earnings season, yet in the face of this bad news, stocks have been charging forward. Add to the mix a rapidly rising rate of new COVID-19 infections, and you get a sense of the market’s clear disconnect. In times like these, traditional metrics alone might not tell the full story. You need other strategies to do the job.The activity of insiders can act as a more reliable trading signal. Who are these people in the know? They are the corporate officers and board members standing at the helm, entrusted with the task of steering their companies in the right direction. Given the nature of their positions, they have access to information before the general public, and thus, i...

Yahoo | July 16, 2020

Vaccinex (VCNX) Catches Eye: Stock Jumps 8.1%

Vaccinex (VCNX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Yahoo | July 7, 2020

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease

Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, today announced that, notwithstanding the challenges posed by the ongoing COVID-19 pandemic, it remains on track to complete the potentially pivotal SIGNAL trial in HD within the anticipated time frame. Primary efficacy data has been collected from all subjects who completed the study except for 2 subjects whose assessments were delayed by the COVID-19 pandemic, but whose clinical sites have now reopened and who are expected to complete efficacy assessments later this month. The Company continues to anticipate that database lock will be completed by September and that topline data may be released by early October as previously guided.

Yahoo | July 7, 2020

Versatile Vaccinex Needs A Trial Or Partner Win, But Scaled Down Operation May Be More Likely

Investment Thesis Vaccinex share price performance since IPO. Source: TradingView. A review of Vaccinex's (VCNX) recent share price performance and funding runway might persuade investors to leave this early stage biotech stock well alone, but there is also a case to be made that the stock represents a risky potential...

Edmund Ingham on Seeking Alpha | June 30, 2020

Read More 'VCNX' Stories Here

VCNX Price Returns

1-mo 16.13%
3-mo 36.71%
6-mo -4.26%
1-year 8.83%
3-year N/A
5-year N/A
YTD 11.34%
2019 33.06%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9626 seconds.